MedTrace Logo

A Six-Week Safety Study of an Investigational Ophthalmic Solution

NCT01698814 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 518

Last updated 2014-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AL-4943A Ophthalmic Solution

DRUG

AL-4943A Ophthalmic Solution Vehicle

Inactive ingredients used as placebo

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Terri Pasquine · Alcon Research

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-01-31
Completion
2013-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01698814 on ClinicalTrials.gov